INS and type 2 diabetes mellitus: Studies suggest that compared to individuals with T2D receiving insulin, those who received GLP-1RAs had a significantly reduced risk of developing 10 of 13 common obesity-associated cancers, such as the following (from lowest to highest risk): gallbladder; meningioma; pancreatic; hepatocellular; ovarian; multiple myeloma; esophageal; endometrial; colorectal; and kidney cancer [9,34,35].